OTC dermatology market study
This article was originally published in The Tan Sheet
Executive Summary
The "threat from the herbal medications market" is one of the anticipated restraining factors for the acne medicated products market in the next few years, Frost & Sullivan says in a recently released study on the U.S. OTC dermatology products market. With estimated revenues at $194.78 mil. in 1997, Frost & Sullivan expects the acne products category to grow $249.52 mil. in 2003. The other top "restraints" are increased competition between branded products as well as between branded and generic products, while the top "drivers" for the category are increasing number of teenagers, product diversification and increasing usage rates, the report says. The entire dermatology market, $2.2 bil. in 1997, will reach $2.53 bil. in revenues by 2003, the report notes...